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The endocrine activity of the gastroin-
testinal tract has been studied for more 
than a century, with gut hormones such as 
secretin emerging from the seminal stud-
ies of Bayliss and Starling (1). The concept 
that the gut also controlled pancreatic 
islet secretions was supported by experi-
ments demonstrating that administration 
of crude gut extracts lowered blood glu-
cose in animals. The development of the 
insulin radioimmunoassay enabled the 
description of the incretin effect, namely 
that glucose administered into the gut 
potentiated insulin secretion to a greater 
extent than isoglycemic stimulation of 
insulin secretion achieved through i.v. 
glucose administration. The first incretin 
hormone, glucose-dependent insulinotro-
pic polypeptide (GIP), was isolated by John 
Brown in the 1970s (2). Here, we describe 
the discovery and characterization of the 
second incretin hormone, GLP-1. We high-
light 3 decades of science from multiple 
laboratories supporting the development 
of GLP-1– and GLP-2–based therapies. 
GLP-1 is now used for the treatment of 
type 2 diabetes (T2D) and obesity, whereas 
GLP-2 is used for the therapy of short bow-
el syndrome (SBS).
Discovery of GLP-1
Although GIP was isolated through classical 
peptide purification and protein sequenc-
ing methodology, the discovery of the 
GLP-1 sequence stemmed from the appli-
cation of recombinant DNA approaches 
developed in the laboratories of Stanley 
Cohen, Paul Berg, and Herb Boyer in the 
early 1970s. This remarkable new techn-
ology allowed for a rapid and accurate 
prediction of the amino acid sequences of 
proteins by the decoding of the nucleotide 
sequences of cloned recombinant cDNA 
copies of messenger RNAs. The Habener 
lab utilized this technology to elucidate 
proglucagon amino acid sequences from 
cDNAs and genes isolated from angler-
fish in the early 1980s (3–5) and the rat 
proglucagon cDNA and gene sequences 
followed shortly thereafter (refs. 6, 7, Fig-
ure 1, and Figure 2). Corresponding pro-
glucagon sequences from hamster, bovine, 
and human were identified by Graeme 
Bell and others in the early 1980s (8–10). 
These sequences revealed that glucagon 
and re lated GLP sequences were encoded 
by larger protein precursors, termed pre-
prohormones (Figure 2). The anglerfish 
preproglucagons (Figure 2A), isolated and 
characterized by Lund and Goodman (3–5), 
were interesting as there were two different 
cDNAs encoded by separate (nonallelic) 
genes and they each contained a glucagon- 
related sequence, in addition to glucagon. 
The two anglerfish glucagon–related pep-
tides resembled GIP, a glucoincretin hor-
mone released from the gut into the circu-
lation during meals, subsequently shown 
by Dupre and Brown in 1973 to augment 
glucose-dependent insulin secretion (11). 
Unlike the two anglerfish preproglucagons, 
each of which harbored glucagon and a sin-
gle glucagon-related peptide, the mammali-
an preproglucagons all contained glucagon 
and two additional glucagon-related pep-
tides, designated GLP-1 and GLP-2 (Figure 
2B). Notably, the corresponding amino acid 
sequences of the GLP-1s in the four mam-
malian species were identical (12), with 
conservation of sequence implying as yet 
unknown but potentially important biolog-
ical actions of GLP-1.
Collectively, these findings further 
supported the evolving notion at the 
time that small peptide hormones are 
synthesized in the form of larger prohor-
mones and that the final bioactive pep-
tides are formed posttranslationally by 
selective enzymatic cleavages from the 
prohormones (Figure 2B). Earlier studies 
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The discovery, characterization, and clinical development of glucagon-like-
peptide-1 (GLP-1) spans more than 30 years and includes contributions from 
multiple investigators, science recognized by the 2017 Harrington Award 
Prize for Innovation in Medicine. Herein, we provide perspectives on the 
historical events and key experimental findings establishing the biology 
of GLP-1 as an insulin-stimulating glucoregulatory hormone. Important 
attributes of GLP-1 action and enteroendocrine science are reviewed, with 
emphasis on mechanistic advances and clinical proof-of-concept studies. 
The discovery that GLP-2 promotes mucosal growth in the intestine is 
described, and key findings from both preclinical studies and the GLP-2 
clinical development program for short bowel syndrome (SBS) are reviewed. 
Finally, we summarize recent progress in GLP biology, highlighting emerging 
concepts and scientific insights with translational relevance.
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note, in addition to glucagon, the pancreas 
contained a large peptide with immuno-
reactive determinants for both GLP-1 and 
GLP-2 (but not glucagon), consistent with 
incompletely cleaved proglucagon (major 
proglucagon fragment [MPGF]) (Figure 3, 
A and C, and ref. 19). In contrast to find-
ings in pancreas, immunoreactive GLP-1 
peptides detected in gut extracts consisted 
entirely of smaller peptides (refs. 15 and 
16, and Figure 3, B and C). These findings 
indicated that the cleavage of proglucagon 
into small GLP-1–immunoreactive pep-
tides was more efficient in the gut com-
pared with pancreas. These observations 
were also consistent with the incretin con-
cept in which, in response to oral nutrients, 
glucoincretin hormones such as GIP (and 
subsequently GLP-1) originate from the 
gut and not the pancreas.
Svetlana Mojsov in the Habener lab-
oratory detected glycine-extended and 
arginine-amidated isoforms of GLP-1 — as 
well as both the amino-terminally extended 
peptides GLP-1(1-37) and GLP-1(1-36)amide 
and the amino-truncated peptides GLP-1 
(7-37) and GLP-1(7-36)amide — in extracts 
of pancreas (Figure 3A). Nevertheless, the 
abundance of these peptides was much 
greater in the gut (20).
Bioactivities of the GLP-1 
peptides
The earliest studies of the bioactivities of 
GLP-1(1-37) were indecisive. One study 
found that the 37 amino acid peptide 
activated adenylyl cyclase in membranes 
prepared from rat pituitary and hypothal-
amus (21), whereas another study failed to 
detect any effects of the peptide on glucose 
and insulin in cortisone-treated rabbits 
GLP-1(7-37). Further, at the carboxyl- 
terminal region of the putative GLP-1 pep-
tide resides a sequence RGRR predicting 
a prohormone convertase–directed cleav-
age site followed by an amidation of the 
penultimate arginine by a peptidylglycine 
α-amidating monooxygenase (14) result-
ing in peptides of 36 and 30 amino acids, 
GLP-1(1-36)amide and GLP-1(7-36)amide.
The availability of the amino acid 
sequences of GLP-1 and GLP-2 obtained 
from the decoding of the nucleotide 
sequences based on the genetic code 
allowed for the chemical synthesis of the 
predicted peptides, examination of their 
biological activities, and preparation of 
peptide-specific antisera. Daniel Drucker 
joined the Habener laboratory in the sum-
mer of 1984, with the original intent of 
studying the molecular control of thyroid 
hormone biosynthesis. However, the thy-
roid group, led by Bill Chin, was decamp-
ing for the Brigham and Women’s Hospi-
tal, and Daniel was assigned to work on the 
proglucagon gene. To understand whether 
proglucagon might be processed to yield 
multiple proglucagon-derived peptides 
(PGDPs), including GLP-1 and GLP-2, 
Drucker transfected a proglucagon cDNA 
expression vector into fibroblasts, pituitary 
cells, and islet cells (15). Although minimal 
processing was observed in fibroblasts, 
immunoreactive GLP-1 and GLP-2 was 
detected by chromatography and radio-
immunoassays in medium and extracts 
from transfected pituitary and islet cells 
(15). Application of similar chromatogra-
phy and radioimmunoassay techniques 
in studies of rat (16), pig (17), and human 
(18) tissues revealed distinct profiles of 
PGDPs in pancreas and gut (Figure 3). Of 
had demonstrated that insulin and para-
thyroid hormone are synthesized as pre-
prohormones. The hydrophobic amino 
terminal sequences, termed the pre- or 
signal sequences, are cleaved from the 
nascent polypeptide chains during their 
translation on ribosomes, leaving the 
prohormones as the precursor of the 
peptide hormones. The A and B chains 
of insulin and parathyroid hormone were 
found to be cleaved from their respective 
prohormones by the actions of specific 
endopeptidases, prohormone conver-
tases, which cleave proteins at the sites 
of two consecutive basic amino acids, 
arginine and lysine (13). These earlier 
findings of prohormone convertase spec-
ificity were applied to deduce potential 
cleavage sites in proglucagon.
Structure-activity properties  
of GLP-1
Examination of the amino acid sequence 
of proglucagon initially presented a 
conundrum regarding the processes by 
which potentially bioactive GLP-1 pep-
tides might be liberated from the pro-
hormone (Figure 2B). In keeping with 
the rule that bioactive peptides are 
cleaved from prohormones at sites con-
sisting of two basic amino acids (13), 
several investigators initially predicted 
that bioactive GLP-1 would be a peptide 
of 37 amino acids beginning with histi-
dine and ending in glycine, GLP-1(1-37). 
However, further inspection of the pro-
hormone sequences revealed a second 
single basic amino acid followed by his-
tidine residing 6 amino acids carboxyl- 
proximal to the first histidine, predict-
ing a GLP-1 peptide of 31 amino acids, 
Figure 1. Historical timeline depicting seminal events in the discovery and development of gluca-
gon-like peptide therapeutics.
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bioactivities for the extended forms, GLP-1 
(1-37) and GLP-1(1-36)amide, have yet been 
determined. Furthermore, no distinctive bio-
logical activities have been attributable spe-
cifically to the amidated forms of GLP-1.
The view from Denmark
In Copenhagen, Jens Holst and colleagues 
were interested in the incretin effect and 
were studying the condition of postpran-
dial reactive hypoglycemia after gastric 
surgery (27). This type of hypoglycemia 
was clearly hyperinsulinemic, yet the sig-
nal for insulin secretion was unknown. 
Looking for possible candidates, they were 
inspired by Lise Heding’s work on gluca-
gon and her identification of the immu-
nological differences between gut and 
pancreatic glucagon (28). Knowing that 
glucagon would stimulate insulin secre-
tion, they were interested in the numer-
ous cells in the gut that produce immu-
noreactive glucagon (29). Eventually, this 
work led to the identification of glicentin 
and oxyntomodulin (Figure 2B), which 
both contain the full glucagon sequence, 
explaining the immunoreactivity in the 
gut (30–32).
Having identified all of the molecular 
components of glicentin also in the pan-
creas (33), they proposed that glicentin 
represents at least part of a common gut 
and pancreatic glucagon precursor, which 
undergoes differential processing in the 
two tissues, a hypothesis subsequently con-
firmed through identification of the human 
proglucagon gene by Graeme Bell and col-
leagues (7). However, it was also clear that 
proglucagon was larger than glicentin, and 
the interest focused on peptides contained 
within the MPGF representing the remain-
der of proglucagon (minus glicentin) (34). 
The early work decoding the anglerfish 
proglucagon cDNA by Lund and Habener 
(3) followed by elucidation of the ham-
ster proglucagon cDNA by Graeme Bell 
(9) supported a hypothesis that cleavage 
of MPGF might result in liberation of the 
GLPs. The Holst group quickly developed 
radioimmunoassays for GLP-1 and GLP-2 
to test this hypothesis. To their excitement, 
they found that MPGF was indeed differ-
entially processed in the gut, but not in the 
pancreas, to yield two GLPs (ref. 17 and 
Figure 3C). However, using the perfused 
pancreas preparation, they soon realized 
that neither of the two GLPs used in these 
The demonstration that GLP-1 directly 
increased cAMP levels provided condi-
tional evidence for the existence of a Gs 
protein-coupled receptor in β cells. In 
studies of insulin secretion using the iso-
lated perfused pancreas, Mojsov and Weir 
demonstrated that GLP-1(7-37) and not 
GLP-1(1-37) stimulated insulin secretion 
at concentrations as low as 50 pM (ref. 24 
and Figure 5, A–C). Likewise, as outlined 
below, Jens Holst and colleagues showed 
that luminal glucose stimulated GLP-1 
secretion from the perfused intestine (Fig-
ure 5D), and doses from 500 pM to 5 nM 
GLP-1(7-36)amide stimulated insulin secre-
tion in the perfused pig pancreas (Figure 
5E and ref. 25). Thus, it turned out that a 
cleavage in proglucagon at the single basic 
amino acid, arginine, and not the double 
basic amino acids, generated the active 
GLP-1 peptides, GLP-1(7-37) and GLP-1 
(7-36)amide (Figure 5C). First in man studies 
reported in December 1987 by Kreymann 
and Bloom (26) rapidly established the 
insulinotropic actions of GLP-1(7-36)amide 
in human subjects. Although numerous 
studies have demonstrated that the amino- 
terminally truncated forms of GLP-1, GLP-
1(7-37), and GLP-1(7-36)amide are active 
glucoregulatory hormones, no compelling 
(22). To determine whether the shorter 
GLP-1 isoforms were bioactive, Drucker 
incubated truncated forms of GLP-1 with 
multiple cell lines, examining cell growth, 
gene expression, and signal transduc-
tion. Remarkably, insulin-producing islet 
cells responded to N-terminally truncated 
forms of GLP-1, exhibiting increased lev-
els of cyclic AMP accumulation within 
minutes of exposure to 50 pM–5 nM GLP-
1(7-37) (Figure 4A). In contrast, neither 
glucagon, GLP-1(1-37), or GLP-1(1-36)–
NH2 increased cAMP accumulation at 
these concentrations (23). GLP-1(7-37) 
also increased the levels of insulin mRNA 
transcripts and stimulated insulin secre-
tion at 25 mM but not 5.5 mM glucose in 
studies with isolated islet cell lines (Figure 
4, B and C, and ref. 23). In contrast, nei-
ther glucagon nor GLP-2 induced insulin 
gene expression. Furthermore, GLP-1 
(7-37) had no effect on levels of angioten-
sin gene expression in the insulinoma cell 
line and did not change levels of glucagon, 
prolactin, and corticotropin mRNAs in islet 
or pituitary cell lines (23). Hence, these 
findings (Figure 4, A–C) published in 1987 
(23) established that GLP-1(7-37) directly 
augments glucose-dependent insulin bio-
synthesis and secretion from β cells.
Figure 2. Structure and processing of anglerfish and human proglucagon. Representation of the 
structures of proglucagon cDNAs from Anglerfish (A) and Human (B), with tissue-specific liberation of 
individual proglucagon-derived peptides in pancreas or intestine. PC1, prohormone convertase 1; PC2, 
prohormone convertase 2; MPGF, major proglucagon fragment. Arrows in A represent sites of cleave by 
prohormone convertase enzymes.
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Mentlein in Kiel, Holst and Deacon showed 
that the GLP-1 molecule was cleaved by the 
enzyme dipeptidyl-peptidase-4(DPP-4) 
in vivo and that inhibitors of this enzyme 
could completely protect the molecule 
(43). In fact, the circulating half-life of 
GLP-1 was only 1.5–2 minutes in human 
subjects with diabetes, and they proposed 
that inhibitors of DPP-4 could maintain 
higher levels of intact active endogenous 
GLP-1 for therapeutic purposes (44). Sub-
sequent studies soon demonstrated that 
DPP-4–resistant GLP-1 analogues were 
longer-acting than native GLP-1 (45). Fur-
thermore, inhibitors of DPP-4 completely 
prevented the breakdown of GLP-1 in the 
circulation and amplified the insulinotro-
pic actions of GLP-1 (46). This exciting 
development, presented in a Perspectives 
article in Diabetes in 1998 (47), was soon 
followed by the development of clinically 
useful inhibitors, first vildagliptin and sub-
sequently sitagliptin.
It remained to be understood whether 
GLP-1 receptor agonists would actually 
be useful for clinical diabetes therapy or 
whether tachyphylaxis would develop 
upon chronic administration. The group 
in Copenhagen administered synthetic 
GLP-1 by constant s.c. infusion for 6 
weeks to a group of individuals with 
long-standing T2D (48). Fortunately, no 
tachyphylaxis was observed; GLP-1 ther-
apy reduced fasting and mean plasma 
glucose by 4.3 and 5.5 mmol/l; glycated 
hemoglobin by 1.3 %; and body weight by 
2 kg. Moreover, insulin sensitivity and β 
cell function, assessed by clamp studies, 
greatly improved. Importantly, no limit-
ing side effects were re corded (48), pro-
viding proof of concept in 2002 for GLP-1 
therapy in subjects with T2D. It was now 
clear that GLP-1–based therapies had tre-
mendous potential.
The Toronto perspective: 
the physiology of GLPs and 
discovery of GLP-2
Building on the availability of cloned pro-
glucagon gene sequences in the Habener 
lab (6), Daniel Drucker and Jacques 
Philippe pursued the analysis of the molec-
ular control of islet α cell proglucagon 
gene expression in the mid 1980s (49, 50). 
Upon returning to Toronto in 1987, Druck-
er extended these studies to examine pro-
glucagon gene expression in the intestine 
stimulating activity attenuated as plasma 
glucose levels started to fall, limiting the 
fall to 0.5–1 mmol/l.
At that time, the Copenhagen group 
realized that GLP-1 was extremely interest-
ing and, in further studies, demonstrated 
that it strongly inhibited gastric motility 
and gastric and pancreatic exocrine secre-
tion (39), consistent with an important 
role for this hormone as a regulator of 
upper gastrointestinal function. They also 
demonstrated that infusions of GLP-1 in 
humans inhibited appetite and food intake, 
actions subsequently exploited in the clinic 
to treat obesity (40). In studies published 
in 1993 by Michael Nauck and colleagues 
in Göttingen, i.v. infusion of GLP-1 com-
pletely normalized severely elevated fast-
ing glucose concentrations in patients with 
long-standing T2D as a consequence of the 
actions of GLP-1 to stimulate insulin and 
inhibit glucagon secretion (41). Although 
GLP-1 clearly had therapeutic potential, 
s.c. injections of GLP-1 were disappoint-
ingly ineffective (42). The explanation was 
an extremely rapid metabolism and inacti-
vation of GLP-1. With inspiration from Rolf 
studies had any effect on pancreatic hor-
mone secretion. They therefore decided 
to isolate the naturally occurring hormone 
from porcine and human and gut extracts, 
and they found that the naturally occur-
ring peptide was a truncated from of GLP-1 
representing proglucagon (aa 78-108) 
(Figure 5C) and subsequently found to be 
amidated, corresponding to proglucagon 
78-107amide (35). Importantly, this hormone 
was potently insulinotropic (Figure 5E and 
ref. 25), so they had also described a new 
incretin hormone in 1987; however, they 
wondered whether GLP-1 was more inter-
esting than the already known incretin 
GIP, which exhibited a diminished effect 
on insulin secretion in patients with T2D 
(36). They soon found, using the perfused 
pancreas, that GLP-1 — in contrast to GIP — 
also powerfully inhibits glucagon secretion 
(37). Eventually, they demonstrated that 
during infusions of physiological amounts 
of GLP-1 into humans, insulin secretion 
would be stimulated and glucagon secre-
tion inhibited, resulting in a decrease in 
hepatic glucose production (38). However, 
the effect was self-limiting, with the insulin- 
Figure 3. Processing of proglucagon and glucagon-like peptides in the pancreas and intestine. 
Detection of immunoreactive forms of GLP-1 in extracts from rat pancreas (A) and intestine (B) as 
adapted from ref. 16. Characterization of proglucagon-derived peptide immunoreactivity secreted 
from perfused pig pancreas and intestine (C) using peptide-specific antisera reveal tissue-specific 
posttranslational processing of the PGDPs, as outlined in ref. 17.
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the Drucker lab demonstrated that native 
GLP-2 robustly increased small bowel 
growth in Fischer 344 rats with an inac-
tivating mutation in the Dpp4 gene (60). 
Furthermore, a GLP-2 analogue with a sin-
gle amino acid substitution [Gly2]-GLP-2 
exhibited substantial resistance to DPP-4 
cleavage and robust intestinotrophic activ-
ity in normal rats in vivo (60). Hence, the 
importance of DPP4 for cleavage of both 
GLP-1 and GLP-2 became evident very 
early in the study of the GLPs.
The identification of GLP-2 as an 
intestinal growth factor spurred a series 
of experiments examining the actions of 
GLP-2 in the context of experimental gut 
injury. GLP-2 administration was gener-
ally associated with preservation of gut 
mucosal structure and function in the 
setting of chemical, radiation, or surgical-
ly induced intestinal injury in preclinical 
studies (61–63). Notably, GLP-2 also rapid-
ly increased nutrient absorption in normal 
rodents (64) and in animals with surgical 
gut resection mimicking SBS (65). Excit-
ingly, the findings in animals were soon 
extended to humans with SBS. In a pilot 
study carried out around 2000–2001, 
Jeppesen and colleagues demonstrated 
that native GLP-2 administered twice dai-
ly for 35 days increased nutrient absorp-
tion, energy absorption, and weight gain 
in human subjects with SBS (66). These 
findings, namely expansion of intesti-
nal mucosal surface area coupled with 
Two unexpected observations were 
made during isolation of GLUTag cells. 
First, mice harboring s.c. GLUTag cell 
tumors exhibited a marked reduction 
of pancreatic islet α cell mass (57). Sec-
ond, mice with s.c. GLUTag, InR1-G9, or 
RIN1056A glucagon-producing tumors 
all exhibited marked enlargement of the 
small bowel. These findings led Drucker 
to reinvestigate the link between glucagon- 
producing tumors and gut growth, first 
reported in a human subject studied at the 
Hammersmith hospital in 1970 by Dowl-
ing and colleagues in London (58). A series 
of simple experiments from the Drucker 
lab published in 1996 identified GLP-2 as 
the PGDP with the most potent intestino-
trophic activity in mice (58). Remarkably, 
although immunoreactive GLP-2 had been 
detected in intestinal extracts of various 
species (refs. 16, 59, and Figure 3), no pre-
vious biological activity had yet been iden-
tified for GLP-2 in vivo.
The actions of GLP-2 to stimulate 
small bowel growth were rapid, detectable 
within days, and associated with increased 
crypt cell proliferation (58). Surprising-
ly, when similar doses of GLP-2 were 
administered to rats, intestinal growth 
was not significantly increased, although 
an increase in crypt plus villus height was 
observed (60). With hindsight, these find-
ings reflected the importance of DPP-4 for 
the degradation of GLP-2, more evident 
in rats than in mice. Subsequent studies in 
and CNS. He isolated human neonatal 
brainstem cDNAs encoding proglucagon, 
which exhibited an identical sequence to 
that described for islet proglucagon (51). 
Molecular cloning of the rat intestinal pro-
glucagon cDNA similarly revealed an open 
reading frame identical to that elucidated 
for the rat pancreatic islet proglucagon 
cDNA (52). Moreover, in studies carried 
out in collaboration with Patricia Brubak-
er, forskolin, cholera toxin, and dibutyryl 
cyclic AMP increased the synthesis and 
secretion of intestinal PGDPs from primary 
cultures of rat intestinal cells (52). At the 
time, there were no differentiated GLP-1–
secreting enteroendocrine cell lines suit-
able for studies of intestinal proglucagon 
gene expression. Accordingly, Ying Lee, a 
fellow in the Drucker laboratory, generated 
a transgenic mouse expressing the SV40 T 
antigen cDNA under the control of the pro-
glucagon gene promoter. This transgenic 
mouse reproducibly developed GLP-1– 
secreting enteroendocrine tumors of the 
colon (53), enabling isolation of the first 
differentiated GLP-1–producing entero-
endocrine L cell line in 1992, designated 
GLUTag cells. GLUTag cells were easily 
propagated ex vivo; secreted immunoreac-
tive GLP-1, glicentin, oxyntomodulin, and 
GLP-2 in response to cyclic AMP analogues 
(54, 55); and resembled primary cultures 
of nonimmortalized gut endocrine cells 
in regard to their response to a battery of 
secretagogues (56).
Figure 4. GLP-1 directly stimulates signal transduction and glucose-dependent insulin secretion in islet cells. GLP-1(7-37) directly stimulates cyclic AMP 
accumulation (A), insulin gene expression (B), and glucose-dependent insulin secretion (C) in a rat insulinoma cell line, as adapted from ref. 23.
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generation of Glp1r–/– mice. These ani-
mals generated by Louise Scrocchi exhib-
ited impaired oral glucose tolerance and 
reduced insulin levels after glucose stim-
ulation, demonstrating the critical role of 
endogenous GLP-1 as an incretin hormone 
in 1996 (69). Unexpectedly, Glp1r–/– mice 
also exhibited fasting hyperglycemia, and 
impaired i.p. glucose tolerance, establish-
ing the importance of the GLP-1 for β cell 
function beyond its original description as 
an incretin. Moreover, GLP-1R–deficient β 
cells exhibit enhanced sensitivity to apop-
totic injury, whereas pharmacological acti-
vation of GLP-1R signaling attenuated β 
cell death in mice in vivo, as well as in cul-
tures of purified rat β cells studied ex vivo 
(70). The importance of GLP-1R signaling 
for the response to cellular stress was high-
lighted by findings that activation of GLP-
1R signaling attenuated the development 
of ER stress in β cells by enhancing ATF-4 
induction and accelerating recovery from 
translational repression via augmentation 
of ER stress–stimulated ATF-4 translation 
(71). Collectively, these findings explain 
how GLP-1, despite acting to simultane-
ously enhance insulin biosynthesis and 
secretion, maintains functional β cell mass 
through attenuation of ER stress.
The actions of GLP-1 to stimulate insu-
lin and inhibit glucagon secretion, together 
with its inhibitory effects on food intake 
and gastric emptying, spurred considerable 
effort in development of GLP-1–based ther-
apeutics. Remarkably, the first GLP-1R ago-
nist approved for clinical use was exenatide 
(synthetic exendin-4), a peptide originally 
isolated from Heloderma suspectum lizard 
venom by John Eng in 1992 (72). Subse-
quent molecular cloning studies published 
by the Drucker laboratory in 1997 demon-
strated that the lizard genome contains 
two distinct proglucagon gene sequences 
encoding GLP-1 and a separate proexendin 
gene, largely restricted in its expression to 
the salivary gland (73). The original clinical 
development program for exendin-4 uti-
lized twice-daily injections of the unmodi-
fied peptide. Pivotal studies in subjects with 
T2D ultimately resulted in the approval 
of twice-daily exenatide, the first GLP-1R 
agonist in 2005 (Figure 1). These efforts 
spurred the development of a once-weekly 
form of exenatide in a microsphere suspen-
sion, ultimately the first once-weekly ther-
apy approved for diabetes in 2012 (Figure 
in increased fluid and energy absorption, 
while reducing the requirements for PN, in 
two separate placebo-controlled Phase 3 
studies (67, 68). Teduglutide was approved 
for chronic therapy of subjects with 
PN-dependent SBS in the US in Decem-
ber 2012 (67).
The physiology of GLP-1 action
Complementary studies in the Drucker lab 
were focused on defining the physiological 
importance of endogenous GLP-1 through 
enhanced nutrient absorption (67), togeth-
er with substantial preclinical data, sup-
ported the initiation of a drug development 
program to test the efficacy of GLP-2 in 
human subjects with parenteral nutrition– 
dependent (PN-dependent) SBS. Clinical 
studies were initiated with h[Gly2]-GLP-2, 
a degradation-resistant GLP-2 analogue 
discovered in the Drucker lab (60) and sub-
sequently designated teduglutide. Once 
daily teduglutide administration in human 
subjects with PN-dependent SBS resulted 
Figure 5. Truncated forms of GLP-1 stimulate glucose- 
dependent insulin secretion. GLP-1(7-37) (A) but 
not GLP-1(1-37) (B) stimulates insulin secretion from 
the perfused rat pancreas as adapted from ref. 24. 
Sequences of GLP-1(1-37), GLP-1(7-37), and GLP-1 
(7-36amide). (C) Intraluminal glucose stimulates entero-
glucagon, GLP-1, and GLP-2 secretion from the perfused 
pig ileum (D), as adapted from ref. 17. Demonstration 
that GLP-1(7-36)amide stimulates insulin secretion from 
the perfused pig pancreas (E), as adapted from ref. 25.
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clusions surrounding receptor expression 
and localization.
Elucidation of the physiological roles 
of endogenous GLP-1 and GLP-2 in 
humans has been limited in part due to lim-
itations associated with the available antag-
onists. Exendin(9-39) has been widely 
used as a GLP-1 receptor antagonist, yet 
only in short-term human studies. It seems 
likely that more selective antagonists with 
optimized pharmacokinetic profiles would 
advance our understanding of the impor-
tance of endogenous GLP-1 action. Similar-
ly, GLP-2(3-33), often employed as a GLP-2 
receptor antagonist, is both a weak antago-
nist and a partial agonist, and little data is 
available to date that illuminates the phys-
iological importance of endogenous GLP-2 
in human subjects.
Analysis of proglucagon synthesis and 
secretion in rare enteroendocrine L cell 
populations in the small and large bowel 
is also technically challenging. Transgenic 
technologies have enabled isolation of pri-
mary L cell populations suitable for secre-
tion and electrophysiological analyses 
(91), and stem cell–derived gut organoids, 
including those of human origin, herald 
considerable potential for generation of 
diverse enteroendocrine cell populations 
from different sites along the gastrointes-
tinal tract (92). Remarkably, despite the 
theoretical potential of enhancing L cell 
secretion for the treatment of metabolic 
disorders (1), there has been scant progress 
in clinical development of GLP-1 secret-
agogues exhibiting sustained efficacy in 
both preclinical and clinical studies.
GLPs: current use and future 
considerations
What does the second decade of GLP-1–
based therapies portend? Currently, multi-
ple GLP-1R agonists are indicated for the 
treatment of T2D, and liraglutide is also 
approved for obesity; however, indica-
tions such as nonalcoholic steatohepatitis, 
Parkinson’s disease, and Alzheimer’s dis-
ease are being explored. Indeed, several 
randomized controlled clinical trials have 
demonstrated significant clinical improve-
ment in human subjects with Parkinson’s 
disease (93). Despite the appeal of cur-
rent GLP-1R agonists for the treatment of 
T2D, market penetration for many GLP-1R 
agonists remains disappointing, raising 
questions about the potential clinical 
classes used for treatment of T2D, the GLP-
1R agonists and SGLT-2 inhibitors, produce 
weight loss, effective reduction of A1c, a low 
incidence of hypoglycemia, and reductions 
in rates of major adverse cardiovascular 
events and cardiovascular death (75, 87).
Challenges in studies of GLP-1 
and in development of GLP-1R 
agonists
In the era of rapid daily progress in bio-
medical science, it is surprising that it 
took almost 20 years from identification 
of GLP-1 to successful approval of the 
world’s first clinically utilized GLP-1R ago-
nist. The rapid renal clearance of many 
small peptides like GLP-1, together with 
its inactivation by DPP4, required devel-
opment of longer-acting peptides with 
greater stability and enhanced resistance 
to DPP-4. The development of nausea 
and vomiting, encountered in every GLP-1 
development program, often limited dose 
escalation and likely delayed introduc-
tion of GLP-1R agonists, utilized at higher 
doses, with greater efficacy. Indeed, it has 
now become apparent that rates of nau-
sea and vomiting can be greatly reduced 
with much slower titration regimens, as 
has been the case in development of titrat-
able GLP-1–insulin combination therapies. 
Indeed, the development of liraglutide for 
obesity using a 3-mg daily dosing regimen 
further illustrates that much greater toler-
ability to GLP-1 can be achieved using pro-
gressive stepwise titration regimens.
Studies of GLP-1 synthesis, secretion, 
and action have also been hampered by 
lack of suitable reagents and experimental 
challenges. Circulating GLP-1 levels are 
very low, and measurement of GLP-1 in 
the circulation is technically challenging; 
indeed, not all commercial assays pro-
duce consistent or accurate results, and 
many exhibit problematic sensitivity and 
specificity (88). Similar challenges sur-
round the quantitative detection of GLP-2 
(89), which is challenging to measure with 
available commercial assays. Comple-
mentary problems have been identified 
with the antisera used to detect the GLP-1 
and GLP-2 receptors, with problematic 
antisera utilized in dozens of publications. 
The majority of commercially available 
antisera used to detect GLP-1R and GLP-
2R exhibit impaired sensitivity and speci-
ficity (67, 90), challenging published con-
1). Exenatide once weekly was more effec-
tive than the twice-daily preparation, with 
greater reduction of glycemia and compa-
rable control of body weight (74). Today, 
multiple GLP-1R agonists (small peptides 
and high molecular weight proteins) are 
approved for the treatment of T2D, and a 
single drug, liraglutide, was approved for 
the treatment of obesity in 2014 (Figure 1).
The widespread distribution of GLP-1 
receptors in extrapancreatic tissues stimu-
lated considerable research into the nong-
lycemic actions of GLP-1. Indeed, we now 
understand that GLP-1 controls inflam-
mation (75), reduces experimental kidney 
injury (76), and like GLP-2, acts as a potent 
intestinal growth factor through mech-
anisms including stimulation of crypt 
fission (ref. 77 and Figure 6). Among the 
actions of GLP-1 that have engendered the 
most interest are its effects in the cardio-
vascular system. Native GLP-1 increases 
flow-mediated vasodilation, enhances 
heart rate (HR) and cardiac output, and 
is cardioprotective in preclinical studies, 
most notably in animals with ischemic 
cardiac injury (78). Although degradation- 
resistant GLP-1R agonists have minimal 
effects on blood vessels (79), they increase 
HR and reduce cardiac inflammation 
and infarct size in animals with experi-
mental myocardial infarction (75, 80). 
Understanding the mechanisms through 
which GLP-1 exerts cardioprotection is 
challenging, since the GLP-1R is largely 
expressed in atrial and not ventricular car-
diomyocytes (81). Furthermore, the GLP-
1R–dependent control of inflammation in 
heart and blood vessels is complex, as the 
predominant site of GLP-1R expression in 
the (murine) immune system is within the 
intestinal intraepithelial lymphocyte (82).
Several cardiovascular outcome stud-
ies have documented the safety of GLP-1R 
agonists in human subjects with T2D and 
preexisting cardiovascular disease (83, 84). 
Excitingly, reduction of major adverse car-
diovascular events was reported in human 
subjects treated with long-acting liraglutide 
and semaglutide (85, 86). These findings, 
revealed more than a decade after the first 
approval of twice-daily exenatide in 2005, 
have rekindled enthusiasm for the use of 
GLP-1R agonists, alone or in combination, 
in the treatment of T2D and obesity, most 
compellingly in subjects at high risk for car-
diovascular disease. Today, only two drug 
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therapy of bariatric surgery–associated 
hypoglycemia (98). Whether exendin(9-39) 
will exhibit sustained efficacy and safety 
and be similarly useful for treatment of 
genetic forms of hyperinsulinemic hypo-
glycemia requires further study. The elevat-
ed levels of GLP-1 detected in most subjects 
after bariatric surgery are widely viewed as 
contributing to the enhanced β cell function 
and reduced appetite evident in these sub-
jects (99). Nevertheless, insulin sensitivity 
is also rapidly improved after bariatric sur-
gery, and some studies suggest that GLP-1 
(9-36) and its degradation products, which 
circulate at elevated levels after bariatric 
surgery, may enhance insulin sensitivity 
in peripheral tissues. Further research into 
the potential contribution of these PGDPs 
in the context of bariatric surgery may illu-
minate the role(s) of these peptides in this 
unique clinical context.
The cardiovascular safety and benefits 
(Figure 6) associated with the use of GLP-
1R agonists (75) raises further clinically 
relevant questions. Might nondiabetic 
subjects with obesity expect comparable 
cardioprotection with sustained GLP-1R 
agonism? Alternatively, can we identify 
the cardioprotective mechanisms of GLP-1 
action and extend the therapeutic possi-
bilities of GLP-1 therapy to nondiabetic 
subjects at high risk for cardiovascular dis-
ease? Similarly, will human subjects with 
prediabetes, or those at low risk for cardio-
vascular disease, be suitable candidates 
for GLP-1R agonism without long-term 
data establishing durability and reduction 
of complications? Additional clinical trials 
will be required to answer these questions.
The translational success of GLP-1 from 
bench to bedside reflects important contri-
butions from dozens of colleagues studying 
GLP-1 over 3 decades, to whom we extend 
our thanks and appreciation. The history of 
GLP-1 science provides instructive lessons 
relevant to modern-day experimentation 
and drug development. First, the field was 
built slowly with a series of nonflashy yet 
solid studies examining the physiology, 
pharmacology, and pleiotropic actions of 
native GLP-1 and multiple GLP-1R agonists. 
From the onset, the availability of the native 
peptide enabled rapid proof of concept in 
human subjects, quickly validating discov-
eries made in preclinical studies. Most of 
the early, and the majority of subsequent, 
GLP-1 studies were published in tradition-
current expense of and unfamiliarity with 
these new drugs may limit their appeal 
in some markets. Whether longer-acting 
versions, perhaps weekly insulin–GLP-1 
combinations, are feasible and efficacious 
requires additional investigation. More-
over, GLP-1 may yet emerge as an ideal 
partner for peptide combinations that 
enable greater weight loss. Unimolecular 
coagonists and triagonists exhibit substan-
tial preclinical efficacy (95) and are under 
active clinical investigation. Nevertheless, 
it may be challenging to predict the ideal 
ratio(s) of 2–3 peptide epitopes combined 
in a single therapy that produces enhanced 
control of metabolic disease, while main-
taining an acceptable safety profile (96).
The observations that GLP-1R signal-
ing in β cells is essential for control of insu-
lin secretion, together with data suggesting 
that exendin(9-39) may attenuate insulin 
secretion through reduction of β cell cyclic 
AMP (97), has supported investigational 
use of exendin(9-39) for the treatment of 
severe hyperinsulinemic hypoglycemia. 
Preliminary short-term data supports the 
feasibility of using exendin(9-39) in the 
appeal, expense, and commercial success 
of newer formulations. Ongoing attempts 
to improve the therapeutic efficacy of GLP-
1R agonists, exemplified by once-weekly 
semaglutide for diabetes or once-daily 
semaglutide for obesity, are under active 
investigation. ITCA-650 is a long-acting 
version of exenatide enabling sustained 
peptide delivery with implantation of a 
small s.c. osmotic minipump every 3–6 
months. Semaglutide is also being stud-
ied as a once-daily oral formulation (94), 
potentially extending the appeal of GLP-
1R agonists to a subset of patients that may 
traditionally eschew injectable therapies.
Considerable effort is being expended 
to combine the established efficacy of 
GLP-1R agonism with additional thera-
pies, enabling greater therapeutic efficacy 
delivered through a single injection. Two 
insulin–GLP-1 combination therapies 
have been approved, lixisenatide-insulin 
glargine and liraglutide-insulin degludec, 
enabling enhanced control of glucose 
without weight gain. These fixed-ratio 
combination therapies represent attractive 
options for some patients; however, the 
Figure 6. The pleiotropic local and systemic actions of GLP-1 and GLP-2 secreted in response to 
nutrients, bacterial metabolites, or inflammatory toxins and cytokines, from enteroendocrine L 
cells of the small and large intestine.
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al physiology or endocrinology subspe-
cialty journals and might be described as 
“descriptive” or “incremental” by many col-
leagues. The elusive distribution of GLP-1 
receptors, often expressed in small numbers 
of endocrine cells, CNS or enteric neurons, 
or rare immune cells, makes it challenging 
to decisively identify cells, pathways, and 
reductionist mechanisms linking recep-
tor engagement to physiological actions 
and therapeutic efficacy. Nevertheless, 
the multiple actions of GLP-1, described 
in dozens of laboratories, have largely 
been reproducible, and occasional ques-
tionable findings and controversies have 
been extensively studied and subsequently 
discarded by more careful investigation 
(100). Taken together, the story of the dis-
covery and characterization of the GLPs 
highlights how old-fashioned biochemistry, 
physiology, molecular biology, and tradi-
tional analyses of hormone action provides 
a firm scientific foundation for the devel-
opment of multiple novel therapeutics for 
the treatment of obesity, diabetes, and 
intestinal disorders.
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